AMGN Amgen Earnings and EPS analysis

?
Relative Growth: Rel. Growth: 81
Relative Strength: Rel. Strength: 57
Relative Valuation: Rel. Valuation: 64
Relative Profitability: Rel. Profitability: 97

EPS in 2025 (TTM): $13.03

Last Report Period Date: Sep 30, 2025

As of November 2025, AMGN's current EPS stands at $13.03, according to the latest financial reports. For the year 2024, the company recorded an earnings per share (EPS) of $7.62, which marks a drop compared to its EPS of $12.56 in 2023. AMGN reported an EPS of $5.98 for the quarterly report ending on Sep 30, 2025.

AMGN earnings history

Historical annual and quarterly earnings per share (EPS) data for Amgen
EPS (TTM)
$13.03
EPS Growth YoY (Quarterly)
13.5%
EPS (Quarterly)
$5.98
EPS Growth (Quarterly)
124.8%

For 2024, Amgen's EPS was $7.62, a drop of 39.3% from $12.56 in 2023. For the fiscal quarter that ended on Sep 30, 2025, the per-share earnings was $5.98, showing a 13.5% increase from the same quarter last year. For the twelve months ending September 2025, the EPS is $13.03. For the year 2023, the yearly earnings per share was $12.56, marking an increase of 3.1% from 2022.

AMGN EPS growth

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
13.5%
EPS growth YoY
-39.3%
EPS growth 3Y avg
-9.7%
EPS growth 5Y avg
-10.1%

Amgen has registered an increase in EPS of 13.5% during the last 12 months (YoY, quarterly). Examining a broader timeline, the company maintained an average EPS growth rate of -9.7% per year for the last three years. Amgen had an average annual EPS growth rate of -10.1% during the last 5 years. A 10-year view shows that AMGN has seen an average EPS growth of 1.1% per year.

AMGN Earnings Waterfall

Breakdown of revenue, profit and net income for Amgen

AMGN Earnings vs Peers

What are the earnings of AMGN compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BIIB Biogen Inc 13.96 39.8% 2.4% -18.7%
PFE Pfizer Inc 14.31 273.7% -28.7% -13.2%
ABT Abbott Laboratories 15.57 133.8% 24.5% 29.9%
BMY Bristol Myers Squibb Co 15.65 -213.7% N/A N/A
JNJ Johnson & Johnson 17.83 -57.9% -9.7% 0.4%
GILD Gilead Sciences Inc 24.27 -91.6% -57.5% -38.3%
AMGN Amgen Inc 24.55 -39.3% -9.7% -10.1%
ILMN Illumina Inc 27.39 -4.8% N/A N/A
LLY ELI LILLY & Co 45.18 102.1% 24.1% 5.7%
ABBV AbbVie Inc 162.98 -12.1% -28.2% -14.7%

All data is based on quarterly TTM periods, unless otherwise specified.